Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple MyelomaReport as inadecuate


Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma


Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma - Download this document for free, or read online. Document in PDF available to download.

1

Divison of Oral Surgery and Orthodontics, Medical University of Graz, 8010 Graz, Austria

2

Oral and Maxillofacial Surgery of the Mediplus Clinic, 55128 Mainz, Germany

3

Konzept Pharma Service GmbH, 31084 Freden, Germany





*

Author to whom correspondence should be addressed.



Academic Editor: Patrick Schmidlin

Abstract Medication-related osteonecrosis of the jaw is a known side-effect of antiresorptive therapy in patients with malignant diseases. Nevertheless, the exact pathogenesis is still unknown and published prevalences show a significant range. The aim of the presented paper was to assess the prevalence of osteonecrosis ONJ in breast cancer, prostate cancer, and multiple myeloma patients receiving parenteral antiresorptive therapy. For this reason a PubMed search was performed and 69 matching articles comprising 29,437 patients were included in the analysis. Nine-hundred fifty-one cases of jaw necrosis were described. The overall ONJ-prevalence was 2.09% in the breast cancer group, 3.8% in the prostate cancer group, and 5.16% for multiple myeloma patients. View Full-Text

Keywords: osteonecrosis; bisphosphonate; denosumab; multiple myeloma; breast cancer; prostate cancer osteonecrosis; bisphosphonate; denosumab; multiple myeloma; breast cancer; prostate cancer





Author: Petra Rugani 1,* , Christian Walter 2, Barbara Kirnbauer 1, Stephan Acham 1, Yvonne Begus-Nahrman 3 and Norbert Jakse 1

Source: http://mdpi.com/



DOWNLOAD PDF




Related documents